| Item | Amount | Y/Y |
|---|---|---|
| Revenue | ¥0.63B | +107.5% |
| Gross profit | ¥0.21B | — |
| Operating income | ¥0.06B | — |
| Net income | ¥0.05B | +7.4% |
| Gross margin | 33.6% | Net margin 8.4% |
| Revenue Q/Q | +2.3% | — |
The filing did not disclose a revenue breakdown for this period.
| Item | Amount | % of revenue |
|---|---|---|
| Cost of revenue | ¥0.42B | 66.4% |
| R&D | ¥0.16B | 26.0% |
| SG&A | ¥0.04B | 5.7% |
| Tax & other | ¥0.01B | 1.1% |
The Sankey chart shows how revenue splits into cost of revenue, R&D and SG&A, and what remains as profit — clean visuals for research decks and social posts.
佩蒂股份 ・ 宇信科技 ・ 建科院 ・ 华大基因 ・ 英科医疗 ・ 中科信息 ・ 电连技术 ・ 隆盛科技 ・ 英搏尔 ・ 朗新科技 ・ 海特生物 ・ 中石科技
Source: Eastmoney · This page shows public filing data only, not investment advice. · Browse all companies